FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Wednesday

 

Amarantus Releases Preliminary Data From Blood-Based MS Diagnostic

























Amarantus BioScience has released preliminary data from a blood test for multiple sclerosis (MS) called the MSPrecise diagnostic. The company believes that the test could lead to more accurate diagnoses of MS early in the disease’s progression.

MSPrecise is a DNA sequencing test designed to identify specific DNA mutations that are associated with the immune system, and more specifically, a type of immune system cell known as a B cell. The assay is intended to identify patients with relapsing-remitting multiple sclerosis (RRMS).

Click to learn more about a new SPMS clinical trial enrolling in Australia and New Zealand.
MS is characterized by an autoimmune attack on myelin, the substance that insulates nerve cells, allowing them to conduct impulses and communicate. When immune cells damage myelin in the nervous system, MS symptoms result, including loss of movement, pain, vision loss and sensory problems.

Amarantus scientists recently tested the MSPrecise diagnostic by using cerebrospinal fluid (CSF) samples taken from people with MS. The test achieved a 86% sensitivity and 71% specificity to correctly identify early-stage RRMS. Sensitivity refers to the number of people with the condition correctly identified. Specificity refers to correct identification of people who do not have the condition. When combined with a different test, called an oligoclonal banding test (OCB), sensitivity was even better, at 96% and specificity improved to 83%.

On May 11, Amarantus Diagnostics reported findings obtained using blood samples from the same people with MS. The MSPrecise blood assay showed 81% sensitivity and 89% specificity for identifying early-stage RRMS. The results have not yet been combined with an OCB test.

“These early findings are encouraging, and provide a pathway to further define and refine the MSPrecise blood assay,” stated Colin Bier, Chief Development Officer of Amarantus Diagnostics. “Of particular importance, in this initial blood study, is the promising and positive analytical performance. There is such a high rate of misdiagnosis of MS, especially upon first clinical presentation of this chronic and extremely debilitating disease, that a blood test would be of great benefit to patients and physicians. We are preparing MSPrecise CSF for a CLIA-enabling validation study and, in parallel, will actively continue research and development of the MSPrecise blood assay.”

“MSPrecise is potentially a groundbreaking advancement for the diagnosis of multiple sclerosis. Based on the CSF validation data, we anticipate moving into a CLIA validation that is currently in the planning stages,” noted Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “The MSPrecise CSF assay, along with our LymPro Test® blood diagnostic for Alzheimer’s disease, are the two of key assets in our diagnostics division. Together, MSPrecise and LymPro will allow Amarantus Diagnostics to very rapidly achieve critical mass as one of the premier neurodiagnostic testing companies in the world.”

Early identification of RRMS could aid in treatments and possibly in preventation of myelin degeneration, hopefully slowing or even halting MS progression.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News